The discovery of the BCR::ABL1 fusion gene in CML, for example, led to the development of TKIs, such as imatinib, which have revolutionized CML management [15]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.